IPSEN (OTCMKTS:IPSEY) Sets New 1-Year High - Should You Buy?

Key Points

• IPSEN (OTCMKTS:IPSEY) has reached a new 52-week high of $35.12 during trading, reflecting a 7.5% increase from its previous close of $33.19.
• The company is involved in developing treatments in oncology, neuroscience, and rare diseases, with several products currently in various phases of clinical trials.
• IPSEN has a fifty-day moving average price of $33.74 and a 200-day moving average price of $31.00, indicating positive momentum in its stock performance.

IPSEN (OTCMKTS:IPSEY - ) hit a new 52-week high during trading on Thursday . The stock traded as high as $35.12 and last traded at $35.12, with a volume of 122 shares traded. The stock had previously closed at $33.19.

IPSEN Trading Up 7.5%

The company has a fifty day moving average price of $33.74 and a 200 day moving average price of $31.00.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.